We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Clooper is a property management platform. The company argues that 86% of private landlords in the UK manage their properties themselves, with many finding it time-consuming and stressful. Clooper seeks to solve this problem with a property management platform that connects landlords, tenants, trade services, and homeowners to facilitate easy transactions between them. It aims to be a significant contender in the £11 billion property management platform. The company points out that Paul Rothwell of Empire, a large residential landlord in England, has pledged £200,000 of investment to the company. Clooper aims to make move-ins quicker, repairs faster, and payments easier in the wake of Covid-19 which is fuelling the adoption of online services in the UK. The company will use the investment to hire key recruits, operationalise mobile apps, boost marketing, and enhance sales and operations.

Pitch Rated

85%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £409,847
Biohm is an eco-conscious bio-technology company that is revolutionising construction through nature-inspired innovation. The company has adopted methods such as circular construction system, biomimicry, and triagomy. Some of the company’s carbon-negative bio-based materials include building insulation made out of Mycelium (the root structure of mushrooms) and ORB (Organic Refuse Biocompound), a 100% natural sheet material made out of food and agricultural surplus. For its innovation, Biohm won the Waitrose and Partners Plan Plastic Prize: The Million Pound Challenge and a Power to Change grant worth £600,000 to build sustainable living premises. It has also been shortlisted as one of The United Nation’s ‘Young Champions of the Earth’. The company will use 38% of the investment to grow its team, 22% to scale Research and Development (R&D), 22% to protect its Intellectual Property (IP), and 18% for product accreditation.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £790,700
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £194,100
Plug-N-Go is a company that provides electric vehicle charging infrastructure with the aim of sustainably electrifying transport. The company has 24 charge points that are accessible to users via its app. It sources 100% renewable energy from its partners at Octopus Energy. Air pollution is contributing to 40,000 early deaths a year in the UK that Plug-N-Go is striving to change. The global electric vehicle charging stations market will reach USD 27.7 billion by 2027 from an estimated USD 2.5 billion in 2019. The company hopes to become a strong contender in this segment. Plug-N-Go is in discussions over multi-site agreements with the Co-operative Society and Eden district council and has received interest from Associated British Ports. Its goal is to install 3,800 EV charge points for the public in 5 years at sites where drivers are already parking. The company will use the investment to deliver EV charging stations to businesses across the UK.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £176,008
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £148,736
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Black Ballad (BB) is a subscription media lifestyle platform that uses media, community and data to empower black women in Britain and beyond. The company asserts that since its inception in 2014, it has become a dominant force for Black women in Britain, with thousands of members paying upwards of £4.99 per month or £49 per year to access BB's combination of content, events and lifestyle perks. BB claims that it has been the recipient of over £125,000 in grants from organisations that include NESTA, Deutsche Bank and Kings College London. BB argues that it launched two successful surveys about Black Motherhood and Black Women in Britain producing over 400,000 data points from nearly 6,000 respondents. The company has also signed a content partnership with BBC to launch Steve McQueen's 'Small Axe' mini-series. It will use 35% of the investment on technology evolution, 23% towards content creation, 23% towards audience development and marketing, 13% for business development, and 6% for legal, accounting and miscellaneous expenses.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £337,885
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Propetly is an online platform that acts as a connecting hub between investment providers and global investors in the field of real estate. It enables potential property investors to find, evaluate and calculate their investment project within minutes. With the help of AI-enabled architecture, Propetly can verify transactions on its portal, suggest finance options and ensure complete diligence of the transaction as per industry benchmarks. Given the relative lack of professional and up-to-date property investors in the UK, Propetly aims to become the one-stop-shop for all real estate deals. Its offering has led to Propetly being counted amongst leading PropTech brands in the UK. With the funds received, Propetly will invest in paid advertising and PR, upgrade its AI systems to enable more options are available to customers across wide demographics and human resources.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £235,079
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph